<DOC>
	<DOCNO>NCT00324558</DOCNO>
	<brief_summary>Main objective : To evaluate whether subcutaneous administration ( sc ) Bemiparin ( 3,500 UI/day ) 26 week , start first day chemotherapy ( CT ) , delay tumoral spread increase progression-free survival . Secondary objective : To evaluate whether subcutaneous administration ( sc ) Bemiparin ( 3,500 UI/day ) 26 week , start onset chemotherapy , increase global survival , improve response rate treatment CT + RT ( radiotherapy ) reduce incidence venous thromboembolism ( VTE ) .</brief_summary>
	<brief_title>Adjuvant BEmiparin Small Cell Lung Carcinoma ( ABEL STUDY )</brief_title>
	<detailed_description>There clinical evidence indicative beneficial effect heparin evolution patient cancer . Apart study indirect way demonstrated increase survival oncological patient , present venous thromboembolism episode , treat low molecular weight heparin ( LMWH ) comparison treat non-fractionated heparin ; direct action also demonstrate use heparin survival tumour progression . The administration LMWH together Chemotherapy prove increase survival patient diagnose cancer pancreas relation treat chemotherapy . An increase global survival advance solid tumour , thromboembolic disease , also show . All suggest improvement survival patient observe heparin add usual anti-tumour treatment , especially without spread disease , effect seem independent protection thromboembolic complication .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Small Cell Lung Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Small Cell</mesh_term>
	<mesh_term>Heparin , Low-Molecular-Weight</mesh_term>
	<criteria>1 . Patients 18 year old old , either sex , diagnosis limit small cell lung cancer . 2 . Patients ECOG functional state less equal 2 . 3 . Informed consent participate study . 4 . Patients platelet count 100,000/microlitre hemorrhagic symptomatology . 1 . Curative palliative surgery initial treatment neoplastic condition . 2 . Patients active hemorrhage past two month , organic lesion susceptible bleeding ( e.g . active peptic ulcer , hemorrhagic cerebrovascular accident , aneurysm ) , history clinically evident hemorrhagic episode , major surgery past month , outstanding clinically hemoptysis increase risk bleeding due homeostatic alteration contraindicates anticoagulant therapy . 3 . Known hypersensitivity LMWH , heparin substance porcine origin . 4 . Patients hypersensitivity chemotherapeutic agent use protocol make impossible use antitumoral regime indicate protocol ( cisplatin carboplatin etoposide ) , i.e . hypersensitivity cisplatin carboplatin hypersensitivity etoposide . 5 . Patients congenital acquire bleeding diathesis . 6 . Damage to/ surgical intervention central nervous system , eye ear within past 6 month . 7 . Acute bacterial endocarditis slow endocarditis . 8 . Patients history heparinassociated thrombocytopenia current platelet count &lt; 100,000/mm3 9 . Patients severe renal failure ( serum creatinine 2 mg/dl ) hepatic insufficiency ( value AST and/or ALT &gt; 5 time normal value establish reference range local hospital laboratory ) . 10 . Severe arterial hypertension ( systolic blood pressure 200 mmHg and/or diastolic blood pressure 120 mmHg ) . 11 . Women pregnant breastfeeding , possibility become pregnant study . 12 . Patients suspect inability/or inability comply treatment and/or complete study . 13 . Patients participate another clinical trial do past 30 day . 14 . Patients life expectancy le 3 month . 15 . Patients treatment anticoagulant treatment three month diagnosis tumor .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2012</verification_date>
	<keyword>Bemiparin</keyword>
	<keyword>small cell lung carcinoma</keyword>
</DOC>